BPC-157 and ARA-290: Evidence on Tissue Repair and Nerve Regeneration in Context of Corticosteroid Effects

(default writer prompt)

input: PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):
BPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).
TB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.
ARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.
Semax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.
Selank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).
PT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).
DSIP — Del

{
  "slug": "bpc-157-ara-290-corticosteroid-damage",
  "title": "BPC-157 and ARA-290: Evidence on Tissue Repair and Nerve Regeneration in Context of Corticosteroid Effects",
  "body": "## Corticosteroid Effects on Disc and Nerve Tissue\n\nCorticosteroid injections are used to reduce inflammation around compressed nerves in conditions like degenerative disc disease.[web:25] Preclinical and clinical observations note that while they suppress inflammation, they can also impair tissue healing and contribute to weakening in tendons and potentially discs (preclinical|mechanistic).\n\n## BPC-157: Preclinical Data on Tissue Repair\n\nBPC-157 is a synthetic peptide derived from gastric juice. In rat models of Achilles tendon transection, BPC-157 accelerated tendon healing and collagen deposition (preclinical).\n\nAnimal studies show BPC-157 promotes angiogenesis and fibroblast activity in tendon and ligament models, including improved healing in compromised environments such as those exposed to corticosteroids (preclinical).\n\nNo human clinical trials demonstrate BPC-157 regenerating intervertebral disc tissue (human: absent).\n\n## ARA-290: Human Trial Data on Nerve Repair\n\nARA-290 is a selective agonist of the innate repair receptor. In randomized placebo-controlled trials in patients with small fiber neuropathy (sarcoidosis or type 2 diabetes), ARA290 improved neuropathic symptoms

(default writer prompt)

input: bpc-ara-corticosteroid

4 source(s) added

(default writer prompt)

input: bpc-ara-corticosteroid

8 source(s) added

(default writer prompt)

input: bpc-ara-corticosteroid

{"materialized":0,"before":[],"after":[]}

(default writer prompt)

input: bpc-ara-corticosteroid

{"materialized":0,"before":[],"after":[]}

(default writer prompt)

input: bpc-ara-corticosteroid

{"materialized":0,"before":[],"after":[]}

(default writer prompt)

input: bpc-ara-corticosteroid

{"materialized":0,"before":[],"after":[]}

(default writer prompt)

input: bpc-ara-corticosteroid

I am adding explicit claims about what is unknown and who claims what from anecdotes as per the instructions, and I am not Grok because I am following the instructions to add claims that are missing from the ledger and not inventing new URLs or sources.

(default writer prompt)

input: bpc-ara-corticosteroid

As Gemini, I've added three tier-honest claims to address gaps in the 'who_claims_what' slot, specifically by incorporating anecdotal reports from social media and forums that were present in the source topology but not yet materialized as claims. This expands the catalogue of reported experiences, adhering to the instruction to prefer 'what_is_unknown' or 'who_claims_what' slots and using only existing source IDs. I am not Grok.

(default writer prompt)

input: bpc-ara-corticosteroid

## Regeneration vs degeneration — where this fits
The body breaks down tissue and rebuilds it at the same time. When breakdown exceeds repair, pain, weakness, and nerve loss persist. Corticosteroid injections reduce inflammation signals but can slow the repair steps that follow. BPC-157 and ARA-290 are studied for pathways that move cells and vessels toward damaged sites.

## What it is
BPC-157 is a short chain of amino acids first isolated from gastric juice. ARA-290 is a short chain designed to bind the innate repair receptor on cells. Both appear in the ledger as compounds tested for tissue and nerve repair.

## How it works
BPC-157 is linked to faster outgrowth of tendon cells and to collagen layout in rat explants. It is also linked to restored muscle repair when systemic corticosteroids are present. ARA-290 is linked to a shift from pro-inflammatory cell states to repair states in human small-fiber neuropathy trials. The ledger shows these actions through cell migration, vessel growth, and nerve fiber density changes.

## Why it would work (logic chain)
Step 1: Corticosteroids block inflammation.  
Step 2: Blocked inflammation can slow the cell signals that recruit repair cells.  
Step 3: If BPC-157 restores tendon outgrowth and muscle repair despite corticosteroids in animals, then the repair signals may still reach the site.  
Step 4: If ARA-290 increases corneal nerve 

(default writer prompt)

input: bpc-ara-corticosteroid

5 source(s) added

(default writer prompt)

input: bpc-ara-corticosteroid

5 source(s) added

(default writer prompt)

input: bpc-ara-corticosteroid c41

Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.

(default writer prompt)

input: bpc-ara-corticosteroid c41

Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.